Urinary melatonin concentration and the risk of breast cancer in nurses' health study II

American Journal of Epidemiology

Volumn 181, Issue 3, 2015, Pages 155-162

  Brown, Susan B ^a   Hankinson, Susan E ^a,b,c   Heather Eliassen, A ^b,c   Reeves, Katherine W ^a   Qian, Jing ^a   Arcaro, Kathleen F ^a   Wegrzyn, Lani R ^b   Willett, Walter C ^b,c   Schernhammer, Eva S ^b,c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

6 sulfatoxymelatonin; Breast cancer; Melatonin

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; MELATONIN; 6-SULFATOXYMELATONIN;

CANCER; CONCENTRATION (COMPOSITION); EPIDEMIOLOGY; HEALTH RISK; HEALTH SURVEY; HEALTH WORKER; HORMONE; METABOLITE; URINE; WOMENS HEALTH;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; FEMALE; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; PREMENOPAUSE; REGISTERED NURSE; RISK ASSESSMENT; SMOKING; URINE LEVEL; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CASE CONTROL STUDY; MIDDLE AGED; PROSPECTIVE STUDY; UNITED STATES; URINE;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MELATONIN; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES;

EID: 84922379504     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu261     Document Type: Article

References (28)

1. Megdal SP, Kroenke CH, Laden F, et al. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41(13):2023-2032.
2. Kamdar BB, Tergas AI, Mateen FJ, et al. Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;138(1):291-301.
3. Wang F, Yeung KL, Chan WC, et al. A meta-analysis on dose-response relationship between night shift work and the risk of breast cancer. Ann Oncol. 2013;24(11):2724-2732.
4. Brzezinski A. Melatonin in humans. N Engl J Med. 1997; 336(3):186-195.
5. Vijayalaxmi, Thomas CR Jr, Reiter RJ, et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002; 20(10):2575-2601.
6. Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009;281(1):1-7.
7. Cos S, González A, Güezmes A, et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer. 2006;118(2):274-278.
8. Proietti S, Cucina A, Reiter RJ, et al. Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci. 2013;70(12):2139-2157.
9. Hill S, Frasch T, Xiang S, et al. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther. 2009;8(4): 337-346.
10. Ram PT, Dai J, Yuan L, et al. Involvement of the MT1 melatonin receptor in human breast cancer. Cancer Lett. 2002; 179(2):141-150.
11. Karbownik M. Potential anticarcinogenic action of melatonin and other antioxidants mediated by antioxidative mechanisms. Neuro Endocrinol Lett. 2002;23(suppl 1):39-44.
12. Travis RC, Allen DS, Fentiman IS, et al. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004;96(6): 475-482.
13. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst. 2005;97(14):1084-1087.
14. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008;100(12): 898-905.
15. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1): 74-79.
16. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev. 2010;19(3):729-737.
17. Wu AH, Stanczyk F, Wang R, et al. Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer. 2013;132(4): 891-896.
18. Wang XS, Tipper S, Appleby PN, et al. First-morning urinary melatonin and breast cancer risk in the Guernsey Study. Am J Epidemiol. 2014;179(5):584-593.
19. Sturgeon SR, Doherty A, Reeves KW, et al. Urinary levels of melatonin and risk of postmenopausal breast cancer: Women's Health Initiative observational cohort. Cancer Epidemiol Biomarkers Prev. 2014;23(4):629-637.
20. Schernhammer ES, Rosner B, Willett WC, et al. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 2004;13(6):936-943.
21. Tworoger SS, Eliassen AH, Rosner B, et al. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 2004;64(18):6814-6819.
22. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics. 1983;25(2):165-172.
23. Mirick DK, Davis S. Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev. 2008; 17(12):3306-3313.
24. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005;97(3):125-134.
25. Härtter S, Nordmark A, Rose DM, et al. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol. 2003;56(6):679-682.
26. Dopfel RP, Schulmeister K, Schernhammer ES. Nutritional and lifestyle correlates of the cancer-protective hormone melatonin. Cancer Detect Prev. 2007;31(2):140-148.
27. Schernhammer ES, Kroenke CH, Dowsett M, et al. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res. 2006;40(2): 116-124.
28. Lang U, Kornemark M, Aubert ML, et al. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab. 1981;53(3):645-650.